JPS6284011A - Hair tonic - Google Patents
Hair tonicInfo
- Publication number
- JPS6284011A JPS6284011A JP22319885A JP22319885A JPS6284011A JP S6284011 A JPS6284011 A JP S6284011A JP 22319885 A JP22319885 A JP 22319885A JP 22319885 A JP22319885 A JP 22319885A JP S6284011 A JPS6284011 A JP S6284011A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- dione
- skin
- androstene
- side effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 47
- 230000001256 tonic effect Effects 0.000 title description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000005977 Ethylene Substances 0.000 claims abstract description 16
- 239000000810 peripheral vasodilating agent Substances 0.000 claims description 7
- 229960002116 peripheral vasodilator Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 35
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 abstract description 8
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 239000005556 hormone Substances 0.000 abstract description 6
- 229940088597 hormone Drugs 0.000 abstract description 6
- 229950004580 benzyl nicotinate Drugs 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 abstract description 2
- 229950003631 carpronium chloride Drugs 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 3
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000463 material Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229940098465 tincture Drugs 0.000 description 7
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 6
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 229960000984 tocofersolan Drugs 0.000 description 6
- -1 DL-α-tocopherol nicotinic acid ester Chemical class 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 150000002500 ions Chemical group 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 3
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 241000131283 Cantharis Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 239000006000 Garlic extract Substances 0.000 description 2
- 235000010254 Jasminum officinale Nutrition 0.000 description 2
- 240000005385 Jasminum sambac Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000020706 garlic extract Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- VSINWHDOHWBJCS-UHFFFAOYSA-N (4-hydroxy-3-methoxyphenyl)methyl nonanoate Chemical compound CCCCCCCCC(=O)OCC1=CC=C(O)C(OC)=C1 VSINWHDOHWBJCS-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229930007886 (R)-camphor Natural products 0.000 description 1
- GVJHHUAWPYXKBD-QLVXXPONSA-N (S,R,R)-alpha-tocopherol Chemical compound [H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C GVJHHUAWPYXKBD-QLVXXPONSA-N 0.000 description 1
- MMMPXNOKIZOWHM-UHFFFAOYSA-N 1-octoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCC MMMPXNOKIZOWHM-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-IKTKBOKFSA-N 4-oxo-4-[[(2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OC(CCC(O)=O)=O IELOKBJPULMYRW-IKTKBOKFSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001565298 Tamasa Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-DYCDLGHISA-N deuterio acetate Chemical compound [2H]OC(C)=O QTBSBXVTEAMEQO-DYCDLGHISA-N 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】 [産業上の利用分野] 本発明は優れた養毛効果を持つ養毛料に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a hair nourishing agent having excellent hair nourishing effects.
[従来の技術]
男性型の禿頭や脂漏などの生理学上の(敞候は、男性ホ
ルモンの過剰蓄積に基づく男性ホルモン刺激の増大によ
ると言われているが、最近、毛根、皮脂線などの器官に
おけるこの男性ホルモン活性の本体は、これら標的器官
においてテストステロン(男性ホルモン)がテストステ
ロン−5α−レダクターゼという名の酵素(以下、レダ
クターゼと略す。)によって還元された5α−ジヒドロ
テストステロン(以下、5α−DHTと略す。)である
ことが周知となってきている。即ち、率丸や副腎で作ら
れたテストステロンは血流に乗って皮脂線に行き、皮脂
腺細胞の中にあるレダクターゼによって、より強力な男
性ホルモンである5α−DHTに変換される。この5α
−DHTは細胞内の受容体と結合し、核に働いて皮脂腺
細胞の増殖を促す一方、それ自体が皮脂線細胞外に出て
血流に乗り、毛母の細胞に働き毛球部の毛母細胞の分裂
を抑制し、毛の成長を妨げ、抜毛、脱毛を促進するもの
ときれている。[Prior art] Physiological symptoms such as male-pattern baldness and seborrhea are said to be caused by increased stimulation of male hormones due to excessive accumulation of male hormones. The main body of this androgen activity in organs is 5α-dihydrotestosterone (hereinafter referred to as 5α- It is becoming well known that testosterone produced in the adrenal glands and the adrenal glands travels through the bloodstream to the sebaceous glands, where it is made more powerful by reductase in the sebaceous gland cells. It is converted to the male hormone 5α-DHT.This 5α
-DHT binds to intracellular receptors and acts on the nucleus to promote the proliferation of sebaceous gland cells, while DHT itself exits the sebaceous gland cells and enters the bloodstream, acting on hair matrix cells and acting on the hair at the hair bulb. It is said to suppress the division of mother cells, impede hair growth, and promote hair pulling and hair loss.
[発明が解決しようとする問題点]
従って、男性型の禿頭や脱毛などの徴候は、レダクター
ゼの活性を阻害すること、および5α−DHTと受容体
タンパクとの結合を阻害することにより低減または防止
することがでざると考えられ、この観点に基づいてこれ
までにクロルマジノンアセテート、オレイン酸、リノー
ル酸などの物質が見い出されている。しかしながら、こ
れらの物質はレダクターゼ活性の阻害率は大きくても好
ましくない副作用があったり、5α−DHTと受容体タ
ンパクとの結合阻害率が非常に低かったりして、実質上
の養毛効果に劣るという欠点があった。[Problems to be Solved by the Invention] Therefore, symptoms such as male pattern baldness and hair loss can be reduced or prevented by inhibiting the activity of reductase and the binding of 5α-DHT to receptor proteins. Based on this viewpoint, substances such as chlormadinone acetate, oleic acid, and linoleic acid have been discovered so far. However, even though these substances have a high inhibition rate of reductase activity, they have undesirable side effects, and their inhibition rate of binding between 5α-DHT and receptor protein is very low, so they are inferior to the actual hair growth effect. There was a drawback.
[問題点を解決するための手段]
本発明者らは、上記事情に鑑み、ホルモン作用などの好
ましくない副作用を持たず、安全で、かつレダクターゼ
活性の阻害と、5α−DHTと受容体タンパクとの結合
阻害の両方の効果を併せ持つ物質を探究し、これを配合
することにより養毛効果の優れた養毛料を得るべく鋭意
研究を重ねた結果、4−アンドロステン−3,17−ジ
オン−17−サイクリックエチレンケタールを配合する
ことにより上記目的が達成できることを見い出した(特
開昭6O−136505)。今回、更に研究を進めた結
果、4−アンドロステン−3,17−ジオン−17−サ
イクリックエチレンケタールと皮膚末梢血管拡張剤の一
種または二種以上とを配合することにより、その効果が
相乗的に増大することを見い出し本発明を完成するに至
った。[Means for Solving the Problems] In view of the above circumstances, the present inventors have developed a method that does not have undesirable side effects such as hormonal effects, is safe, inhibits reductase activity, and inhibits 5α-DHT and receptor protein. As a result of intensive research to find a substance that has both the effect of inhibiting the binding of - It has been discovered that the above object can be achieved by blending cyclic ethylene ketal (Japanese Patent Application Laid-Open No. 6O-136505). As a result of further research, we found that by combining 4-androstene-3,17-dione-17-cyclic ethylene ketal with one or more skin peripheral vasodilators, the effect is synergistic. The present invention was completed based on the discovery that
すなわち、本発明は4−アンドロステン−3,17−ジ
オン−17−サイクリックエチレンケタールと、皮膚末
梢血管拡張剤の一種または二種以上とを含有することを
特徴とする養毛料である。That is, the present invention is a hair nourishment characterized by containing 4-androstene-3,17-dione-17-cyclic ethylene ketal and one or more skin peripheral vasodilators.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
4−アンドロステン−3,17−ジオン−17−サイク
リックエチレンケタールの配合量は、本発明の養毛材中
0.0001〜2重量%が好ましい。特に、好ましくは
、0.0001〜2重量%である。0.0001重量%
未満では、養毛効果が発揮できない場合がある。また配
合量が多い程養毛効果は大きいが、多量に用いられた時
の予期せぬ副作用の発現などを考えると、2重量%以下
が好ましい。The blending amount of 4-androstene-3,17-dione-17-cyclic ethylene ketal is preferably 0.0001 to 2% by weight in the hair nourishing material of the present invention. Particularly preferably, it is 0.0001 to 2% by weight. 0.0001% by weight
If the amount is less than that, the hair nourishing effect may not be exhibited. The higher the amount, the greater the hair-nourishing effect, but in view of the possibility of unexpected side effects occurring when a large amount is used, the amount is preferably 2% by weight or less.
本発明において相乗的に養毛効果を増大させる物質であ
る皮膚末梢血管拡張剤は塩化カルプロニウム、ミノキシ
ジル、スピロノラクトン、ビタミンB6塩酸塩、セファ
ランチン(タマサキッヅラフジエキス)、D−カンフル
、DL−カンフル、DL−α−トコフェロール、ヨウ化
ニンニクエキス、DL−α−トコフエロールリルイン酸
エステル、センブリエキス、イノシトールヘキサニコチ
ン酸エステル、ビタミンE1デキストラン硫酸ナトリウ
ム、ニコチン酸、DL−α−トコフェロールニコチン酸
エステル、ニコチン酸ブトキシエチル、γ−オリザノー
ル、ニコチン酸ベンジル、ニコチン酸メチル、ノナン酸
バニリルアミド、コハク酸DL−α−トコフェロール、
tt酸DL−α−トコフェロール、トウガラシチンキ、
カンタリスチンキ、ショウキョウチンキなどであり、セ
ファランチン(タマサキッヅラフジエキス)、DL−α
−トコフェロール、ヨウ化ニンニクエキス、センブリエ
キス、DL−α−トコフェロールニコチン酸エステル、
ニコチン酸ベンジル、ノナン酸パニリルアミド、酢酸D
L−α−トコフェロール、トウガラシチンキ、カンタリ
スチンキ、ショウキョウチンキなどが好ましい。In the present invention, the skin peripheral vasodilators, which are substances that synergistically increase the hair-nurturing effect, include carpronium chloride, minoxidil, spironolactone, vitamin B6 hydrochloride, cephalanthine (Tamasa Kidzurafji extract), D-camphor, DL-camphor, DL-α-tocopherol, iodized garlic extract, DL-α-tocopherol lyric acid ester, Jasmine japonica extract, inositol hexanicotinic acid ester, vitamin E1 dextran sodium sulfate, nicotinic acid, DL-α-tocopherol nicotinic acid ester, nicotine Butoxyethyl acid, γ-oryzanol, benzyl nicotinate, methyl nicotinate, vanillyl nonanoate, DL-α-tocopherol succinate,
DL-α-tocopherol tt acid, capsicum tincture,
Cantharis tincture, ginger tincture, etc., cephalanthine (Tamasakidzurafuji extract), DL-α
-Tocopherol, iodized garlic extract, Jasmine japonica extract, DL-α-tocopherol nicotinic acid ester,
Benzyl nicotinate, nonanoic acid panillylamide, acetic acid D
L-α-tocopherol, capsicum tincture, cantharis tincture, ginger tincture and the like are preferred.
皮膚末梢血管拡張剤の配合量は0.0001〜5重量%
が好ましく、特に好ましくは0.01〜3.0重量%で
ある。0001重量%未満では、養毛効果が発揮できな
い場合があり、5重量%を越えても、それ以上の養毛効
果を期待できない場合がある。The compounding amount of the skin peripheral vasodilator is 0.0001 to 5% by weight.
is preferred, particularly preferably 0.01 to 3.0% by weight. If the amount is less than 0,001% by weight, the hair-nurturing effect may not be exhibited, and even if it exceeds 5% by weight, no further hair-nurturing effect may be expected.
本発明に係る養毛料には上記の4−アンドロステン−3
,17−ジオン−17−サイクリックエチレンケタール
と皮膚末梢血管拡張剤のほか、通常養毛料に用いられる
添加剤、例えば、ヒノキチオール、ヘキサクロロフェン
、フェノール、ベンザルコニウムクロリド、セチルピリ
ジニウムクロリド、ウンテ゛シレン酸、トリクロロカル
バニリドおよびビチオノールなどの抗菌剤、メントール
などの清涼剤、サリチル酸、亜鉛及びその誘導体、乳酸
及び七のアルキルエステルなどの薬剤、オリーブ油、ス
クワラン、流動パラフィン、イソプロピルミリステート
、高級脂肪酸、高級アルコールなどの油分、その他界面
活性剤、香料、酸化防止剤、紫外線吸収剤、色素、エタ
ノール、水、保湿剤、増粘剤などが本発明の効果を損な
わない範囲で適宜配合することができる。The hair nourishment according to the present invention includes the above-mentioned 4-androstene-3.
, 17-dione-17-cyclic ethylene ketal and peripheral skin vasodilators, as well as additives commonly used in hair nourishing products, such as hinokitiol, hexachlorophene, phenol, benzalkonium chloride, cetylpyridinium chloride, untecilenic acid, Antibacterial agents such as trichlorocarbanilide and bithionol, cooling agents such as menthol, drugs such as salicylic acid, zinc and its derivatives, lactic acid and 7-alkyl esters, olive oil, squalane, liquid paraffin, isopropyl myristate, higher fatty acids, higher alcohols. Other oils such as surfactants, perfumes, antioxidants, ultraviolet absorbers, pigments, ethanol, water, humectants, thickeners, and the like can be suitably blended as long as they do not impair the effects of the present invention.
本発明の養毛料の性状は、液状、乳液、軟膏など外皮に
適用できる性状のものであればいずれでもよい。The hair tonic of the present invention may be in any form as long as it can be applied to the outer skin, such as liquid, milky lotion, or ointment.
本発明に係る養毛材は4−アンドロステン−3,17−
ジオン−17−サイクリックエチレンケタールと頭皮の
末梢血管を拡張し血流量の増加を促す皮膚末梢血管拡張
剤とが効果的に作用し、相乗的な養毛効果を発揮するも
のである。The hair nourishing material according to the present invention is 4-androstene-3,17-
Dione-17-cyclic ethylene ketal and a skin peripheral vasodilator that dilates peripheral blood vessels in the scalp and promotes an increase in blood flow act effectively to exert a synergistic hair-nourishing effect.
[実施例]
次に実施例をあげて本発明をざらに詳細に説明する。本
発明はこれにより限定きれるものではない。配合量は重
量%である。[Example] Next, the present invention will be explained in detail with reference to Examples. The present invention is not limited thereby. The blending amount is in weight%.
実施例に先たち試験法を説明する。The test method will be explained in Examples below.
l至羞11主跋
試料使用前後の洗髪時脱毛本数の変化で判定した。被験
者は実施例1〜6及び比較例1の計7種類の各々の郡ご
とに10名とした。測定期間は4力月間とし、前半の2
力月間は試料無塗布の期間、後半の2力月間を試料塗布
の期間とした。この間、2日おきに洗髪して抜毛を回収
し、1週間分をまとめて、その本数を数えた。各期間の
抜毛本数の表示は、試料無塗布の2力月間、計8回の抜
毛本数のデータと養毛剤塗布の2力月間、計8回の抜毛
本数のデータをそれぞれの期間ごとにまとめ、平均値±
αの形で1回当りの抜毛本数として表示した。単位は本
である。効果の判定は、それぞれの期間の平均値の差か
ら次のように表示した。Judgment was made based on the change in the number of strands of hair removed during hair washing before and after using the main hair sample. There were 10 subjects in each of the seven groups of Examples 1 to 6 and Comparative Example 1. The measurement period is 4 months, and the first two
The first month was the period when no sample was applied, and the second half of the second month was the period when the sample was applied. During this period, the hair was washed every two days and the pulled hair was collected, and the number of hairs for one week was counted. To display the number of hairs pulled out in each period, data on the number of hairs pulled out 8 times in total for 2 months without sample application and data on the number of hairs pulled out 8 times in total for 2 months with hair growth agent applied are summarized for each period, and the average is calculated. Value ±
The number of hairs pulled per session was expressed in the form of α. The unit is a book. The effectiveness was determined based on the difference between the average values for each period as shown below.
++:抜毛本数が70本以上減っており著しい効果を認
めた。++: The number of hairs pulled was reduced by 70 or more, indicating a significant effect.
+ :抜毛本数が40本以上減っておりがなりの効果を
認めた。+: The number of hairs pulled was reduced by 40 or more, and an origami effect was observed.
± :抜毛本数が1o本以上減っておりやや効果ありと
いえた。±: The number of hairs pulled was reduced by more than 1o, and it could be said that there was a slight effect.
−:抜毛本数の減少が10本未満であり効果ありとはい
えない。-: The reduction in the number of hairs pulled is less than 10, and it cannot be said that there is an effect.
実施例1.2、比較例1
(以下余白)
(製造法)
95%エタノールに4−アンドロステン−3,17−ジ
オン−17−サイクリックエチレンケタール、ニコチン
酸ベンジル、および硬化ヒマシ油E O(40モル)付
加物を添加し、撹拌溶解させ、次いでイオン交換水を添
加、混合して実施例1の透明液状の養毛材を得た。実施
例2、比較例1も実施例1と同様にして得た。Example 1.2, Comparative Example 1 (blank below) (Production method) 4-androstene-3,17-dione-17-cyclic ethylene ketal, benzyl nicotinate, and hydrogenated castor oil EO ( 40 mol) adduct was added and stirred to dissolve, and then ion-exchanged water was added and mixed to obtain a transparent liquid hair nourishing material of Example 1. Example 2 and Comparative Example 1 were also obtained in the same manner as Example 1.
(以下余白)
前述した結果はすべて、4−アンドロステン−3,17
−ジオン−17−サイクリックエチレンケタールと皮膚
末梢血管拡張剤配合の本発明に係る養毛材が従来公知の
4−アンドロステン−3,17−ジオン−17−サイク
リックエチレンケタールを配合した養毛材に比して、相
乗的にその養毛効果が優れていることを示している。(Left below) All the results mentioned above are based on 4-androstene-3,17
- The hair nourishing material according to the present invention containing dione-17-cyclic ethylene ketal and a skin peripheral vasodilator is a hair nourishing material containing conventionally known 4-androstene-3,17-dione-17-cyclic ethylene ketal. This shows that it has a synergistically superior hair-nourishing effect compared to other materials.
実施例3
(A 相)
4−アンドロステロン−3,17−
ジオン−17−サイクリックエチレン 2.0ケ
タール
センブリエキス 3.0ポリオキ
シエチレン
(60モル)硬化ヒマシ油 2.0グリセリン
7.0ジプロピレングリコ
ール 8.41.3−ブチレングリコー
ル 5.0ポリエチレングリコール150
0 5.0(B 相)
セチルイソオクタネート10.0
スクワラン 5.0ワセリ
ン 2.0プロピルパラ
ベン 2.0(C相)
カルボキシビニルポリマー1%水溶if 30.0へ
キサメタリン酸ソーダ 0.03イオン
交換水 8.95(D 相)
イオン交換水 4.5(E 相
)
カセイカリ 0.12イオ
ン交換水 5.0(製造法)
A相、B相をそれぞれ60℃で加熱溶解し、混合してホ
モミキサー処理しゲルを作る。これにC相を徐々に添加
しホモミキサーで分散する。Example 3 (Phase A) 4-Androsterone-3,17-dione-17-cyclic ethylene 2.0 Ketal assembly extract 3.0 Polyoxyethylene (60 mol) Hydrogenated castor oil 2.0 Glycerin 7.0 Di Propylene glycol 8.41.3-Butylene glycol 5.0 Polyethylene glycol 150
0 5.0 (Phase B) Cetyl isooctanate 10.0 Squalane 5.0 Vaseline 2.0 Propylparaben 2.0 (Phase C) Carboxyvinyl polymer 1% water soluble if 30.0 Sodium hexametaphosphate 0.03 ion Exchanged water 8.95 (D phase) Ion exchanged water 4.5 (E phase) Caustic potash 0.12 Ion exchanged water 5.0 (manufacturing method) Phase A and phase B are dissolved by heating at 60°C, respectively, and mixed. Treat with a homomixer to make a gel. Phase C is gradually added to this and dispersed using a homomixer.
次にこれに溶解したC相を加え、最後に溶解したE相を
添加しホモミキサーで乳化して0/W乳液型の養毛材を
得た。Next, the dissolved phase C was added thereto, and finally the dissolved phase E was added and emulsified with a homomixer to obtain a 0/W emulsion type hair nourishing material.
この養毛材を実施例1.2と同様に実使用テストを行っ
たところ、その養毛効果が優れていることが確認された
。When this hair nourishing material was subjected to a practical use test in the same manner as in Example 1.2, it was confirmed that its hair nourishing effect was excellent.
実施例4
(A 相)
4−アンドロステン−3,17−
ジオン−17−サイクリックエチレン
ケタール 0.2セフアラ
ンチン 5.0流動パラフイン
5.0セトステアリルアルコール
5.1グリセリルモノステアレート
3.0EO(20モル)−2−オクチルドデシルエ
ーテル 3.0
プロピルパラベン 0.3香料
0.1(B 相)
グリセリン 8.0ジプロピレ
ングリコール 20.0ポリエチレングリコ
ール4000 5.0へキサメタリン酸ソーダ
o、oosイオン交換水
45.295(製造法)
A相、B相をそれぞれ加熱溶解して混合し、ホモミキサ
ーで乳化して軟膏状養毛材を得た。Example 4 (Phase A) 4-androstene-3,17-dione-17-cyclic ethylene ketal 0.2 Cephalanthine 5.0 Liquid paraffin
5.0 Cetostearyl alcohol 5.1 Glyceryl monostearate
3.0 EO (20 mol)-2-octyldodecyl ether 3.0 Propylparaben 0.3 Fragrance
0.1 (Phase B) Glycerin 8.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium hexametaphosphate o, oos ion exchange water
45.295 (Production method) Phase A and phase B were respectively heated and dissolved and mixed, and emulsified with a homomixer to obtain an ointment-like hair nourishing material.
この養毛材を実施例3と同様に実使用テストを行ったと
ころ、その養毛効果が優れていることが確認されたち
実施例5
エタノール 55.04−ア
ンドロステン−3,17−ジオン−17−サイクリック
エチレン ケタール 0.0001DL−α−トコ
フェール
ニコチン酸エステル 0.01
EO(8モル)オレイルアルコールエーテル 2.0ヒ
ノキチオール o、05香料
0.1染料
0.0899イオン交換水
42.75(製造法)
エタノールにEO(8モル)オレイルアルコールエーテ
ル、4−アンドローステロン−3,17−ジオン−1フ
ーサイ換水を加えて可溶化し養毛材を得た。When this hair nourishing material was subjected to a practical use test in the same manner as in Example 3, it was confirmed that its hair nourishing effect was excellent.Example 5 Ethanol 55.04-androstene-3,17-dione-17 -Cyclic ethylene ketal 0.0001 DL-α-tocopher nicotinic acid ester 0.01 EO (8 mol) oleyl alcohol ether 2.0 Hinokitiol o, 05 Fragrance
0.1 dye
0.0899 ion exchange water
42.75 (Manufacturing method) EO (8 mol) oleyl alcohol ether and 4-androsesterone-3,17-dione-1 fusai exchange water were added to ethanol to solubilize it to obtain a hair nourishing material.
実施例6
4−アンドロステン−3,17−ジオン−17−サイク
リックエチレンケタール0.2g1シヨウキヨウチンキ
0.0001g、流動パラフィン5.0g、セトステア
リルアルコール5.5g、ワセリン5.5g、グリセリ
ルモノステアレート3.0g、 EO(20モル)−2
−オクチルドデシルエーテル3.0g1プロピルパラベ
ン0.2g、および香料0.1gを加熱溶解、混合する
。これに、グリセリン7.0g、ジプロピレングリコー
ル20.Og、 5.0gのポリエチレングリコール4
000、ヘキサメタリン酸ソーダ0.005gおよびイ
オン交換水45.4949gの熱溶解混合物を添加し、
ホモミキサーにて乳化してクリーム状養毛料を得た。得
られた養毛材は優れた養毛効果を示した。Example 6 4-androstene-3,17-dione-17-cyclic ethylene ketal 0.2 g 1 tincture 0.0001 g, liquid paraffin 5.0 g, cetostearyl alcohol 5.5 g, vaseline 5.5 g, glyceryl mono Stearate 3.0g, EO (20mol)-2
- 3.0 g of octyl dodecyl ether, 0.2 g of propyl paraben, and 0.1 g of fragrance are heated and dissolved and mixed. To this, 7.0 g of glycerin and 20 g of dipropylene glycol. Og, 5.0g polyethylene glycol 4
000, a hot melt mixture of 0.005 g of sodium hexametaphosphate and 45.4949 g of ion exchange water,
The mixture was emulsified using a homomixer to obtain a creamy hair nourishing agent. The obtained hair nourishing material showed an excellent hair nourishing effect.
[発明の効果1
本発明の養毛材は、優れた養毛効果を有し、かつ、局所
的に有効で、全身的には副作用がなく、皮膚刺激性の少
ない、安全性の高い養毛材であ本発明の養毛材は、優れ
た養毛効果を有し、かつ、局所的に有効で、全身的には
副作用がなく、皮膚刺激性の少ない、安全性の高い養毛
材である。[Effect of the Invention 1 The hair nourishing material of the present invention has an excellent hair nourishing effect, is locally effective, has no systemic side effects, has little skin irritation, and is highly safe. The hair nourishing material of the present invention is a highly safe hair nourishing material that has an excellent hair nourishing effect, is locally effective, has no systemic side effects, and has little skin irritation. be.
Claims (1)
リックエチレンケタールと、皮膚末梢血管拡張剤の一種
または二種以上とを含有することを特徴とする養毛料。A hair nourishment containing 4-androstene-3,17-dione-17-cyclic ethylene ketal and one or more skin peripheral vasodilators.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22319885A JPS6284011A (en) | 1985-10-07 | 1985-10-07 | Hair tonic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22319885A JPS6284011A (en) | 1985-10-07 | 1985-10-07 | Hair tonic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6284011A true JPS6284011A (en) | 1987-04-17 |
Family
ID=16794335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22319885A Pending JPS6284011A (en) | 1985-10-07 | 1985-10-07 | Hair tonic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6284011A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60136505A (en) * | 1983-09-26 | 1985-07-20 | Shiseido Co Ltd | Cosmetic |
-
1985
- 1985-10-07 JP JP22319885A patent/JPS6284011A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60136505A (en) * | 1983-09-26 | 1985-07-20 | Shiseido Co Ltd | Cosmetic |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6293215A (en) | Hair tonic | |
| JPH11269043A (en) | Cosmetic for scalp and hair | |
| JPS6293217A (en) | Hair tonic | |
| JPS6360910A (en) | Skin drug for external use | |
| JPS6127914A (en) | Cosmetic | |
| JPS6256411A (en) | Beautifying agent | |
| JP2696523B2 (en) | Anti-dandruff agent and hair cosmetic | |
| JPH08133950A (en) | Skin preparation for external use | |
| JPH0559888B2 (en) | ||
| JPH10279437A (en) | Hair cosmetic | |
| JPH0873340A (en) | Topical skin | |
| JP2566792B2 (en) | Hair growth and hair growth promoter | |
| JPS6284012A (en) | Hair tonic | |
| JPS6284016A (en) | Hair tonic | |
| JPS6284014A (en) | Hair tonic | |
| JP2004026812A (en) | Hair restoration | |
| JPH0577647B2 (en) | ||
| JPH11255621A (en) | Cosmetic for scalp and hair | |
| JPS60215608A (en) | Hair tonic preparation | |
| JPH08133949A (en) | Skin preparation for external use | |
| JPS6284015A (en) | Hair tonic | |
| JPS61238718A (en) | Hair cosmetic | |
| JPS59172412A (en) | Hair tonic | |
| JPS6293214A (en) | Hair tonic | |
| JPS62132810A (en) | Cosmetic |